Citius Pharmaceuticals (NASDAQ:CTXR) Trading 6.1% Higher – Here’s Why
by Amy Steele · The Cerbat GemCitius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) shares traded up 6.1% during mid-day trading on Monday . The company traded as high as $0.8006 and last traded at $0.8006. 304,847 shares were traded during mid-day trading, a decline of 13% from the average session volume of 348,733 shares. The stock had previously closed at $0.7547.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on CTXR shares. Wall Street Zen raised shares of Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, December 27th. D. Boral Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.
Check Out Our Latest Stock Report on CTXR
Citius Pharmaceuticals Price Performance
The stock’s 50-day moving average price is $0.92 and its 200 day moving average price is $1.17. The firm has a market capitalization of $16.62 million, a PE ratio of -0.24 and a beta of 1.61.
Institutional Investors Weigh In On Citius Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. Arkadios Wealth Advisors boosted its position in Citius Pharmaceuticals by 100.0% during the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock valued at $32,000 after purchasing an additional 10,000 shares in the last quarter. XTX Topco Ltd bought a new position in Citius Pharmaceuticals in the second quarter worth about $32,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Citius Pharmaceuticals during the second quarter valued at about $40,000. 16.88% of the stock is currently owned by hedge funds and other institutional investors.
About Citius Pharmaceuticals
Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.
One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.